GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Iran Daru (XTEH:IRDR1) » Definitions » ROCE %

Iran Daru (XTEH:IRDR1) ROCE % : 0.00% (As of . 20)


View and export this data going back to 1990. Start your Free Trial

What is Iran Daru ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Iran Daru's annualized ROCE % for the quarter that ended in . 20 was 0.00%.


Iran Daru ROCE % Historical Data

The historical data trend for Iran Daru's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Iran Daru ROCE % Chart

Iran Daru Annual Data
Trend
ROCE %

Iran Daru Semi-Annual Data
ROCE %

Iran Daru ROCE % Calculation

Iran Daru's annualized ROCE % for the fiscal year that ended in . 20 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: . 20 )  (A: . 20 )(A: . 20 )
=/( ( ( - ) + ( - ) )/ )
=/( (+)/ )
=/
= %

Iran Daru's ROCE % of for the quarter that ended in . 20 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: . 20 )  (Q: . 20 )(Q: . 20 )
=/( ( ( - ) + ( - ) )/ )
=/( ( + )/ )
=/
= %

(1) Note: The EBIT data used here is one times the annual (. 20) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Iran Daru  (XTEH:IRDR1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.


Iran Daru ROCE % Related Terms

Thank you for viewing the detailed overview of Iran Daru's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Iran Daru (XTEH:IRDR1) Business Description

Comparable Companies
Traded in Other Exchanges
N/A
Address
Ayatollah Saeedi Highway, End Of Kermani Street, Moallem Boulevard, Tehran, IRN, 1371658111
Iran Daru is a pharmaceutical company based in Iran. It manufactures and sells pharmaceutical products for antibiotics, cardiovascular agents, and local anesthetic agents. The company manufactures products in three main dosage form categories namely solid, semi-solid, and liquid including tablets, capsules, pellets, sachets, gels, creams, ointments (sterile and non-sterile), spray solutions, and syrups. Products offered by Iran Daru include Diclofenac Potassium, Biotin 5 mg, Tetracycline, Folic acid, Meloxicam, Acetaminophen and Caffeine, and Levocetirizine dihydrochloride, among others. It also exports its products to other countries.

Iran Daru (XTEH:IRDR1) Headlines

No Headlines